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,Mild to moderate hypertriglyceridemia is particularly
common in patients with insulin resistant conditions such
as metabolic syndrome and type 2 diabetes (T2D),1-3 yet
current treatment guidelines do not recommend whether
elevated triglycerides should be treated in order to
decrease CVD events and to which target levels.4 This
situation results in large part from lack of definitive
cardiovascular (CV) outcomes data demonstrating that
reducing triglycerides (TGs) lowers cardiovascular
events.5 Nonetheless, a growing body of evidence has
emerged to support triglyceride-rich lipoproteins (TRLs)
as instigators of atherosclerosis. With escalating rates of
diabetes, obesity, and cardiovascular disease especially in
the developing world, appropriate management of
hypertriglyceridemia is an unresolved issue among
strategies for reducing residual cardiovascular risk.6
Indeed, CVD deaths are projected to exceed 23 million
deaths annually by 2030, and low to middle-income
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Volume 206countries will bear much of this burden (~80% of CVD
deaths) owing to increasing rates of obesity, diabetes, and
dyslipidemia.7,8 The PROMINENT study will test the
hypothesis that TG-lowering with the selective peroxi-
some proliferator activator modulator-α (SPPARM-α)
pemafibrate reduces cardiovascular events in T2D
patients with mild-to-moderate hypertriglyceridemia and
low levels of HDL cholesterol (HDL-C).Rationale
Role of TRLs in atherogenesis
Although low-density lipoprotein cholesterol (LDL-C)
remains unquestionably the chief priority in lipid
management, emerging secondary targets such as sub-
clinical inflammation and hypertriglyceridemia have
garnered considerable attention. While recent large-
scale clinical trial evidence9 supports a role for anti-
inflammatory therapy, robust data for TG lowering
remains elusive and has engendered controversy regard-
ing biologic plausibility.
TGs are the major constituent of TRLs, which include
chylomicrons and very-low-density lipoprotein (VLDL),
synthesized and secreted from intestinal enterocytes and
the liver, respectively, and metabolized in plasma. Dynamic
intravascular remodeling results in a spectrum of particles
(remnant lipoproteins) that are heterogeneous in size,
density, lipid, and protein composition. This process
primarily occurs through hydrolysis of core TGs by
lipoprotein lipase (LPL),10 yielding TRLs progressively
enriched with cholesterol, depleted of TGs and reduced in
size. Someof these particles undergohepatic clearance,while
those in circulation undergo further modification by LPL and
hepatic lipase, with ultimate conversion to cholesterol
enriched LDL. In the absence of robust commercial assays
that capture TRL cholesterol concentration, plasma TG level
serves as the integrated pathway biomarker most commonly
used in clinical and research settings.
Despite strong and consistent epidemiologic associa-
tions between hypertriglyceridemia and incident cardio-
vascular events,11 the scientific community has struggled
to elucidate mechanisms by which hypertriglyceridemia
per se induces atherosclerosis since, in humans, choles-
terol accumulation and not TG accumulation character-
izes atherosclerotic lesions. Thus, most conventional
explanations for increased atherosclerosis susceptibility
do not clarify the observed relationship between
hypertriglyceridemia and increased vascular risk. How-
ever, partially hydrolyzed remnant TRLs share with LDL
the potential to infiltrate the arterial intima and cause
atherosclerosis by delivery of their cholesterol content.
Lipoproteins normally flux into and out of the arterial wall
through transcytosis via specialized transport vesicles having
diameters of 70–100 nm, thus imposing a size restriction to
lipoprotein trafficking. Nascent chylomicrons and VLDL
particles are too large to penetrate the endothelial barrier,but smaller remnant lipoprotein particles having undergone
TG hydrolysis (ie, chylomicron remnants, smaller VLDL, and
IDL) can enter the sub-intimal space. In animal studies
utilizing in situ perfusion systems to quantify arterial transit
and retention of different lipoprotein classes, remnant
lipoprotein particles exhibit a 10-fold lower rate of influx
compared to LDL particles but efflux less readily (~20-fold)
in a size-dependent manner (Figure 1).12 Thus, TRLs have
prolonged residence time within the vascular space.
Additionally, TRLs carry much more cholesterol per particle
than LDL and can therefore promote massive cholesterol
loading, foam cell formation, and the cascade of events
leading to atheromatous disease.13 These concepts and
experimental findings are consistent with the seminal
Zilversmit hypothesis14,15 which proposed that TRLs act
additively to LDL-C via remnant infiltration at the arterial wall.Genetic evidence for a causal role of triglycerides in
atherosclerosis
Because they vary inversely, disentangling the vascular
risk attributable to elevated TGs from that attributable to
low HDL-C has presented an enduring challenge.16 In
prospective studies, adjustment for HDL-C and for other
potential lipid intermediates, largely attenuates the
association between TG concentration and cardiovascu-
lar disease.17 While this statistical adjustment is contro-
versial, these findings served to fuel intensive focus on
potential cardiovascular benefits of therapeutic manipu-
lation of HDL-C. However, HDL-C raising trials18-23 have
proven disappointing and accumulating evidence from
human genetic studies24-26 has now shifted the focus to a
causal role for TRLs in atherothrombosis.
The evidence accrues primarily from studies of genetic
variants that affect LPL activity.27 This enzymeassociateswith
the luminal surface of vascular endothelial cells andpromotes
TG hydrolysis from circulating TRLs, thus reducing plasma
TRL concentration. LPL requires the cofactor apolipoprotein
(apo) C-II for full activation and apo A-V for stabilization and
efficient TG lipolysis.28,29 LPL is further highly regulated by
various proteins, including apo C-III as well as angiopoietin-
like proteins 3 and 4, which all inhibit LPL function. Multiple
lines of evidence frommutational analyses,30-37 genome-wide
association studies,38-41 and Mendelian randomization
studies25,42-45 have shown that higher LPL pathway activity
associates with reduced TGs and is linked causally to lower
CVD risk.46 The ultimate destination of LPL modified TRLs,
whether cleared more efficiently, converted to less athero-
genic intermediates or both, remains unclear.
Almost all genetic variation in TG metabolism identified
in human genetic studies also influences at least one other
lipid trait, usually HDL-C.47 Two notable exceptions are
the studies from Varbo et al43 and Do et al41 Varbo43 et al
used genetic variants associated either selectively with
elevated TRL cholesterol, selectively with both elevated
TRL cholesterol and reduced HDL-C, or selectively with
Figure 1
Comparative analysis of arterial permeability and efflux of isolated lipoprotein fractions.
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elevated TRLs were independently linked with increased
CHD risk while low HDL cholesterol was not. Do et al41
used multivariable Mendelian randomization to separate
TG-associated effects on CHD risk from other lipid
determinants. This analysis reaffirmed an isolated LDL-C
genetic effect and demonstrated an isolated TG genetic
effect, which was similar in magnitude to LDL-C without
altering HDL-C substantially. Exactly which constituent
risk factor or factors is embodied in plasma TG
concentration remains to be fully elucidated, although
as noted above, current best evidence implicates
substrates of LPL pathway modulation. In this framework,
clinical trial evidence is urgently needed to establish
whether potent TG-lowering therapy confers a clinical
benefit commensurate with the promise of epidemiolog-
ic and genetic work in this area.
Selective PPAR-α modulation to reduce residual
cardiovascular risk
Peroxisome proliferator-activated receptors (PPARs)
are nuclear hormone receptors, which bind to DNA as
a heterodimer with the retinoid × receptor (RXR). When
bound together these heterodimeric partners recognize
specific DNA sequences in the vicinity of target genes.The three types of PPARs include α, β, and γ.48 When
activated by the binding of either an endogenous ligand
or synthetic PPAR agonist (such as a fibrate for PPAR-α),
heterodimerization with a ligand-activated RXR results in
a conformational change, leading to the transrepression
or transactivation of target genes. While a large number of
genes carry response elements for PPARs, PPAR-α plays a
key role in metabolic homeostasis as a regulator of lipid
metabolism. Genes regulated by PPAR-α include those
involved in HDL synthesis and metabolism and in VLDL
turnover, among them apo A-I, A-II, A-V and C-III, LPL,
scavenger receptor B1 (SR-B1), the ATP binding cassette
transporters ABCA1 and ABCG1, and acyl CoA synthe-
tase.49-51 PPAR-α additionally regulates the transcription
of LPL itself, and may act through post-translation
mechanisms that affect cellular LPL trafficking.10,52
Pharmacological PPAR-α activation may also participate
in regulation of glucose homeostasis (although the
underlying mechanism in humans is unknown), as well
as reduction in inflammation and thrombogenesis, and
improvement of vascular function.49-51,53
Fibrates currently in clinical use have relatively weak
PPAR-α agonistic potency yet can lower TG concentra-
tions and modestly raise HDL-C levels. Five large
randomized clinical trials have evaluated the effects of
Table I. Effects of fibrates on cardiovascular events in large randomized controlled trials
Trial Drug Patient Characteristics CV Outcome⁎ Trial
Duration
(years)
RR Reduction
Entire Cohort
Atherogenic
Dyslipidemia
Subgroup
RR
Reduction
Subgroup‡
HHS82,83 Gemfibrozil Non-HDL-C N5.2 mmol/l
No CHD
Men
Non-fatal MI
and CHD Death
5.0 −34% (P b .02) TG N204 mg/dL
LDL-C/HDL-C
ratioN 5.0
−71%
(P = .005)
V A -
HIT56,84,85
Gemfibrozil HDL-C b1.0 mmol/l
CHD
Men
Nonfatal MI
and CHD Death
5.1 −22% (P = .006) TG N180 mg/dL
b40 mg/dl
−30%
(P b .05)
BIP86 Bezafibrate Previous MI or angina
Men and women
Fatal/Nonfatal MI
and Sudden Death
6.2 −7% (P = .26) TG ≥200 mg/dL −40%
(P = .02)
FIELD54,87 Fenofibrate Type 2 diabetes
Some patients
receiving statins
Men and women
MI, stroke, CVD
death, coronary or
carotid
revascularization
5.0 −11 (P = .035) TG ≥204 mg/dL
HDL-C b 40 mg/dL (men)
or b50 mg/dL (women)
−27%
(P = .005)
ACCORD55,56 Fenofibrate Type 2 diabetes
CVD or N2 CVD
risk factors
Patients receiving
simvastatin
Men and women
Nonfatal MI, Nonfatal
stroke, and CVD
death
4.7 −8% (P = .32) TG ≥204 mg/dL
HDL-C ≤34 mg/dL
−29%
(P b .05)
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; T2D: Type 2 Diabetes.
To convert TG from mg/dl to mmol/l, multiply by 0.0113; to convert HDL-C from mg/dl to mmol/L, multiply by 0.0259.
⁎ The CV outcome presented is the pre-specified primary endpoint in all trials except FIELD. In this trial, the primary endpoint (CHD) was not reported in. subgroups and the data are
shown for the secondary endpoint of total CVD.
‡Risk reductions and P values for subgroups when not presented in publications by trial investigators were taken from the meta-analysis of Bruckert et al, J Cardiovas Pharmacol
2011;57:267–272.56
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Volume 206fibrates on cardiovascular risk (Table I). Although early
trials suggested benefit of fibrate monotherapy, the more
recent FIELD54 and ACCORD55 studies showed no
benefit of fenofibrate on cardiovascular outcomes in the
setting of background statin therapy (unplanned drop-in
of about 20% in FIELD and by design in ACCORD).
Importantly, none of these trials enrolled participants on
the basis of hypertriglyeridemia and in each trial, post-hoc
subgroup analyses have suggested marked clinical benefit
in this patient population (Table I). For example, in meta-
analyses evaluating subgroup effects,56,57 consistently
greater benefit was found in patients with high TG levels
or mixed dyslipidemia (elevated TG and low HDL-C). In
these subgroups, fibrates appear to reduce cardiovascular
risk by 28% [95% confidence interval (CI), 15% to 39%; P b
.001] or 30% (95% CI, 19% to 40%, P b .0001), respectively,
but only by 6% (95% CI, −2% to 13%, P = .13) in subjects
without these lipid abnormalities.
Advances in approaches to drug discovery and
appreciation of PPAR-α structure and binding properties
has fostered the development of a novel generation of
potent synthetic agonists. PPARs possess a large lipid-
binding pocket that can encompass a range of endoge-
nous ligands.58 On binding, ligands of different structures
can trigger distinct conformational changes in the nuclear
receptor, leading to differential patterns of co-activator or
co-repressor recruitment, which in turn can yield tissue-
and gene-selective effects. Modulating the receptor–
cofactor binding profile of the PPAR by ligands of various
structure offers the opportunity to improve desirablebiological effects (via transactivation of desirable target
genes), and limit known adverse effects (via transrepres-
sion of undesirable genes) of PPAR activation. This
concept provides the rationale for the development of
SPPARMs which induce a differential receptor cofactor
binding profile that aims to confer improved efficacy
while minimizing unwanted side effects.59
Pemafibrate drug development
Pemafibrate (K-877, Parmodia) differs fundamentally in
structure from other currently available PPAR-α agonists and
was designed to optimize potency and diminish unwanted
actions.60 Structurally, pemafibrate (K-877) has an acidic
region as in other PPAR-α agonists, but the addition of
benzoxazole and phenoxyalkyl side-chains, greatly increases
PPAR-α activity and selectivity through comparatively
enhanced interactions with the PPAR-α ligand-binding
pocket.61 In cell-based transactivation assays, pemafibrate
exhibits N2500-fold more potency than fenofibric acid (the
active metabolite of fenofibrate) for human PPAR-α with
N5000-fold greater activity for PPAR-α than either PPAR-γ or
-δ, thus requiringmuch lower doses for lipid effects and thus
limiting unwanted effects.59Pre-clinical data and clinical data
In C57BL/6 J mice consuming a Western diet,
pemafibrate attenuated fasting and postprandial hypertri-
glyceridemia, as well as accumulation of remnant
lipoproteins, by enhancing LPL activity and reducing
Figure 2
Anti-atherogenic effects of pemafibrate in apolipoprotein E transgenic mice.
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to expression of human apoE2 under control of the
endogenous apoE promoter (apoE2KI mice) and consum-
ing a Western diet, administration of pemafibrate at 1/
2500th the dose compared to fenofibrate reduced athero-
sclerotic lesion area to a greater degree (Figure 2).63
Pemafibrate also reduced the expression of inflammatory
mediators including monocyte chemoattractant protein 1
and interleukin-6 mRNA and protein expression in both
cultured THP-1 macrophages and Western-diet fed
apoE2KI mice to a greater extent than fenofibrate.
A worldwide clinical trial program is investigating
pemafibrate as both monotherapy and as add-on to statin
therapy. This program has studied over 2000 patients, the
majority with dyslipidemia and over one-quarter with
concomitant T2D. Table II summarizes the key published
data. A recent study in statin-treated patients64 showed
that pemafibrate (0.4 mg daily) reduced TG ~50%,
lowered Apo C-III by 35–38%, and increased HDL-C by
13–16%.64 LDL-C increased by up to 13%, an effect also
produced by currently available fibrates65,66 and poten-
tially linked to VLDL conversion to LDL particles.67-69
Indeed, pemafibrate significantly decreased apoB by 8%
and non-HDL-C by 8–13%, and lipoprotein analysis
indicated that only large and medium LDL fractions
increased during treatment (Figure 3).64 As such,
pemafibrate improved both the total to HDL cholesterol
ratio and the apo B to apo A1 ratio.
Safety and tolerability
Evidence from the phase II and III studies has shown that
pemafibrate, whether or not co-administered with statins, is
well tolerated with adverse event rates similar to or lower
than those reported for placebo or fenofibrate.64,70-72 In a
phase III study,71 pemafibrate (0.4 mg/d, n = 74) compared
with fenofibrate (106.6 mg/day n = 76) had a lower rate oftotal adverse drug reactions (ADRs) (6.8% versus 23.7%,
respectively; P = .006) with no drop outs due to ADRs. In
addition, in this study, estimated glomerular filtration rate
(eGFR) did not change with pemafibrate, whereas fenofi-
brate was associated with a significant decline in eGFR over
24 weeks (P b .001), consistent with previous findings from
both the FIELD73 and ACCORD74 studies, although revers-
ibility of the effects of fenofibrate on eGFRwas demonstrated
after treatment ended in both those trials. Additional safety
data are shown in Table II. Despite promising phase 2 safety
and efficacy data that support potential clinical benefits of
pemafibrate, two prior short-term clinical trials75 of the
potent PPAR-α agonist LY518674 have been completed and
raised safety concerns. While LY518674 improved athero-
genic dyslipidemia parameters at 12 weeks of therapy,
increased levels of creatinine and LDL-C were observed. The
PROMINENT study will assess whether the favorable safety
profile of pemafibrate persists when administered to a larger
population followed for a substantially longer period of time.Methods
PROMINENT: will targeting triglycerides in high-risk
patientswith type2diabetes ameliorate cardiovascular risk?
The PROMINENT randomized, double-blind, placebo-
controlled trial will test whether treatment of mild to
moderate hypertriglyceridemia with the SPPARM-α,
pemafibrate, reduces cardiovascular events in high risk
patients with diabetes who have elevated TG levels, low
HDL-C levels, and largely already receive aggressive statin
therapy (Figure 4). The trial involves approximately 850
clinical sites in 24 countries and will furnish contempo-
rary information to guide therapeutic decisions in
diabetic patients at residual triglyceride risk for whom
no consistent guideline-based recommendations current-
ly exist. It will also provide high quality data regarding
Table II. Summary efficacy data from published phase II/III clinical trials of pemafibrate
Study Population No.
Participants
Baseline
Statin
Use
Weeks Dose
(mg/day)
Mean Δ
TG
(%)
Mean Δ
HDL-C
(%)
Mean Δ
LDL-C
(%)
Mean Δ
Apo B
(%)
Mean Δ
Creatinine
(mg/dl)
Mean Δ
ALT
(U/L)
70 Japanese
patients with
atherogenic
dyslipidemiaa
224 None 12 Pemafibrate
0.05 −30.9 ± 6.9 +12.0 ± 14.3 +8.9 ± 21.3 −1.4 ± 13.6 −0.011 ± 0.055 −5.9 ± 9.0
0.1 −36.4 ± 6.6 +16.4 ± 16.9 +8.3 ± 29.4 −8.9 ± 13.6 −0.014 ± 0.062 −6.6 ± 10.8
0.2 −42.6 ± 6.7 +16.1 ± 16.7 +5.0 ± 28.0 −7.8 ± 15.0 +0.013 ± 0.049 −7.6 ± 18.1
0.4 −42.7 ± 6.7 +20.5 ± 22.5 +7.4 ± 26.5 −8.1 ± 11.6 +0.050 ± 0.239 −8.7 ± 13.0
Fenofibrate
100 −29.7 ± 6.7 +14.6 ± 16.3 +5.3 ± 23.4 −5.7 ± 14.4 +0.086 ± 0.089 −4.2 ± 13.4
Placebo +28.5 ± 6.8 −2.0 ± 13.5 −6.3 ± 16.2 −2.0 ± 9.9 −0.022 ± 0.064 −1.9 ± 11.6
71 Japanese
patients with
atherogenic
dyslipidemiab
225 None 24 Pemafibrate
0.2 −46.2 ± 2.0 +22.3 ± 15.4 −6.3 ± 19.2 −8.7 ± 15.2 +0.009 ± 0.072 −8.1 ± 13.5
0.4 −45.9 ± 1.9 +17.4 ± 17.7 −3.5 ± 20.0 −5.6 ± 16.2 +0.015 ± 0.065 −4.7 ± 13.4
Fenofibrate
106.6 −39.7 ± 1.9 +17.6 ± 15.0 −6.3 ± 16.9 −9.9 ± 12.9 +0.091 ± 0.097 +1.9 ± 18.5
64 Japanese
patients with
TG ≥200 mg/dl
and non-HDL-C
≥150 mg/dl
treated with
pitavastatin
188 All 12 Pemafibrate
0.1 −46.1 ± 3.9 +13.6 ± 15.4 +1.0 ± 21.6 −8.1 ± 15.1 +0.007 ± 0.060 −1.0 ± 18.3
0.2 −53.4 ± 3.8 +19.7 ± 19.3 +6.6 ± 32.1 −8.6 ± 18.3 +0.014 ± 0.068 −10.1 ± 19.7
0.4 −52.0 ± 3.9 +12.7 ± 19.3 + 2.9 ± 25.8 −7.9 ± 18.6 +0.044 ± 0.080 −9.6 ± 14.2
Placebo −6.9 ± 4.0 +3.4 ± 12.5 −2.3 ± 18.0 −3.3 ± 11.6 −0.011 ± 0.071 +3.4 ± 18.1
64 Japanese
patients with
TG ≥200 mg/dl
treated with
any statin
423 All 24 Pemafibrate
0.2 −46.8 ± 2.6 +17.6 ± 17.2 +8.2 ± 28.3 −7.3 ± 17.6 +0.024 ± 0.079 −12.8 ± 16.8
0.2→0.4 −50.8 ± 2.5 +16.3 ± 14.6 +12.6 ± 38.4 −7.5 ± 19.2 +0.030 ± 0.099 −8.0 ± 17.5
Placebo −0.8 ± 3.0 +4.4 ± 12.7 +3.7 ± 20.0 −3.6 ± 14.9 +0.007 ± 0.071 −0.9 ± 13.8
72 Japanese
T2D patients
with TG
150–1000 mg/
dl
166 39.2% 24 Pemafibrate
0.2 −44.3 ± 3.7 +17.0 ± 17.3 −4.9 ± 23.1 −9.1 ± 15.7 +0.026 ± 0.073 −6.6 ± 13.4
0.4 −45.1 ± 3.6 +9.7 ± 18.3 +1.7 ± 26.2 −1.8 ± 18.3 + 0.031 ± 0.085 −13.1 ± 20.5
Placebo −10.8 ± 3.6 +4.7 ± 12.5 +2.1 ± 15.5 +1.6 ± 11.5 −0.013 ± 0.091 −0.3 ± 18.0
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; T2D: Type 2 Diabetes.
To convert TG from mg/dl to mmol/l, multiply by 0.0113; to convert HDL-C and LDL-C from mg/dl to mmol/L, multiply by 0.0259; to convert Apo B from mg/dl to g/l, multiply by
0.01; to convert creatinine from mg/dl to μmol/l, multiply by 88.4; to convert ALT from U/L to μkat/l, multiply by 0.0167.
a TG 200–499 mg/dl; HDL-C b50 mg/dl in men, HDL-C b55 mg/dl in women.
b TG 150–499 mg/dl; HDL-C b50 mg/dl in men, HDL-C b55 mg/dl in women.
Data are mean ± standard deviation except for TG for which least squares mean ± standard error are presented.
Change in ApoB for reference 79 and serum creatinine for all studies was sourced from the Pharmaceuticals and Medical Devices Agency (PMDA). PARMODIA Table 0.1.
mg: Common Technical Document Summaries. Available from: http://www.pmda.go.jp/drugs/2017/P20170718001/index.html [Accessed 26th December 2017].
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including heart failure, peripheral artery disease, diabetic
retinopathy and nephropathy. Recruitment began in April
2017 and as of April 27th, 2018, 3281 subjects have been
randomized of whom 27.7% are women. Recruitment is
anticipated to complete October 2019.
Study design, objectives, outcomes,
eligibility, statistical analysis, and
oversight
PROMINENT is a phase III, event-driven, double-blinded,
placebo-controlled, multinational, randomized controlled
trial. Figure 2 summarizes the design. Participants must
have T2D with elevated TG [200–499 mg/dl (2.26–5.64
mmol/l)] and low HDL-C [≤40 mg/dl (1.03 mmol/l] and be
on moderate to high intensity statin therapy (either
atorvastatin ≥40 mg/day, rosuvastatin ≥20 mg/day, simva-statin ≥40 mg/day, or pitavastatin 4 mg/day) or have LDL-C
≤70 mg/dl (1.81 mmol/l) within 12 months prior to
enrollment. Statin intolerant participants are eligible if LDL-
C ≤100 mg/dl (2.59 mmol/l). Participants must also have
either prior history of cardiovascular disease (secondary
prevention cohort) or be at high risk defined as age≥ 50
years if male or≥ 55 years if female (primary prevention
cohort). Table III details inclusion and exclusion criteria. The
trial defines prior CVD as previous MI or ischemic stroke,
coronary angiographic evidence of coronary artery disease,
carotid stenosis, symptomatic peripheral artery disease, or
prior arterial revascularization (Table IV).
The trial is sponsored by Kowa Company, Ltd, Nagoya,
Japan. The academic research organization (ARO) is
located at the Center for Cardiovascular Disease Preven-
tion (CCVDP), Brigham and Women's Hospital (BWH),
Boston, MA, USA. The protocol was designed through a
collaboration between CCVDP and the Sponsor (Kowa).
Figure 3
Percent changes from baseline to week 12 in cholesterol content in LDL subclasses measured by high-performance liquid chromatography.
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and Steering Committees, monitors ongoing conduct of
the trial. The study Contract Research Organization
(CRO), IQVIA (Durham, NC, USA) will recruit and
follow-up participants and collect data. Institutional
review boards and health authorities in all participating
countries approved the protocol. All participants provide
written informed consent.
Primary objectives
PROMINENT's primary scientific aim is to assess
whether treatment with the SPPARM-α, pemafibrate 0.2
mg twice daily, compared to placebo reduces time to first
occurrence of the composite outcome of myocardial
infarction, ischemic stroke, hospitalization for unstable
angina requiring unplanned coronary revascularization,
and cardiovascular death. Secondary and tertiary out-
comes are listed in Supplementary Table V and include
individual components of the primary endpoint, all-cause
mortality, hospitalization for heart failure, any coronary
revascularization, new or worsening peripheral artery
disease, change in mechanistic lipid biomarkers as well as
nonfasting remnant cholesterol.
Outcomes
The primary efficacy outcome is the composite of
nonfatal MI, nonfatal ischemic stroke, hospitalization for
unstable angina requiring urgent coronary revasculariza-
tion, and cardiovascular death. Only confirmed primary
endpoints are counted for the primary analysis.
PROMINENT uses the Third Universal Definition of
Myocardial Infarction76 and uses the definitions of
ischemic stroke and cardiovascular death proposed by
Hicks et al77 and Sacco et al78 An independent ClinicalEndpoints Committee (CEC) blinded to study treatment
allocation will adjudicate primary endpoints and a select
number of secondary endpoints (any coronary revascu-
larization, hospitalization for heart failure, and new or
worsening peripheral artery disease.) A separate CEC
Charter fully describes the methods used by the CEC.
Eligibility assessment
The screening approach begins by documentation of pre-
screening evidence of fasting or non-fasting hypertriglyc-
eridemia and lowHDL-C through local laboratory evaluation
within the previous 12 months (Supplemental Figure 1).
Informed consent is obtained at the pre-screening visit with
submission of these values as well as medical record
documentation of T2D, CVD, statin intolerance (if applica-
ble) and LDL-C (if needed to meet inclusion criteria).
Screening (on-protocol) laboratory assessment is then
performed and participants are enrolled into the run-in
period. A single retesting of enrollment TG and/or HDL-C
may occur if subjects are in borderline categories. No subject
may be randomized without meeting entry lipid values or
submission of qualifying medical records. In addition to
eligibility laboratory tests, blood samples are also collected
for advanced lipid testing, glycemic measures, inflammatory
and additional exploratory biomarkers and urine is tested for
microalbuminuria.
Run-in
During the 3 to 5-week placebo run-in period,
potentially eligible subjects receive placebo twice daily,
are assessed for lipid entry criteria (initial and retest, if
needed) and qualifying medical records are collected for
verification of prior cardiovascular disease, T2D, and
statin intolerance when applicable.
Figure 4
PROMINENT Study Design.
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Subjects who complete the run-in period successfully
with high compliance (≥ 75% by tablet count) and meet
lipid eligibility and other clinical criteria are randomized
in a 1:1 ratio to receive pemafibrate or placebo.
Randomization is stratified by age, prior history of CVD,
and statin use at baseline, defined as those who are taking
statins at baseline versus those taking no statins or who
are statin intolerant. Within each stratum, participants are
randomized with equal probability to active pemafibrate
or placebo. A non-fasting sample for lipid testing is
collected at this visit.
Study drug
To improve compliance, safety, and drug accountabil-
ity, all study drug is dispensed in blistered calendar packs
during both the trial run-in and active treatment phase.
Follow-Up
Telephone visits alternate with in-person visits through-
out the treatment period with a greater frequency of visits
occurring during year 1. At each study visit, outcomes
and adverse events are recorded, concomitant medica-
tions documented, and adherence is reinforced. At 2
weeks post randomization, a well-being phone visit is
conducted to provide general support and to reinforce
dosing instructions. Participants are seen at 2, 4, 6, 8 and
12 months and 4-month intervals thereafter. A common
study end date (CSED) visit will be scheduled within a 60-
day window after study termination is announced.Participants will continue study medications through
the CSED unless the study is stopped for evidence of
increased hazard. A post-study safety call will occur
approximately 30 days after the CSED visit at which time
final adverse events and post-study efficacy events will be
collected.
Additional follow-up procedures include collection of
serial information on quality of life and serial specimen
collection for both efficacy and safety assessment and
biobanking. A self-administered quality of life question-
naire (the European Quality of Life 5 Dimensions 5 Level
Questionnaire; EQ-5D-5 L) is completed at randomization,
annually, at the first in-person visit after a primary
endpoint, and at the CSED visit. Fasting blood specimens
for safety and efficacy and urine samples for microalbu-
minuria are collected throughout the study period. Non-
fasting specimens are collected at 6 months. At enroll-
ment, randomization, and 4 months post-randomization,
willing participants donate blood and DNA specimens for
archiving in the central biobank.
Post-randomization lipid-lowering therapy
Phase 2 studies have shown that pemafibrate modestly
but statistically significantly increases LDL-C concentra-
tionwithout increasing LDL particles. A favorable shift in
LDL particle size distribution accompanies this elevation
in LDL-C level, specifically a rise in large and medium LDL
subclasses, a decrease in smaller LDL subclasses, and an
overall decrease in non-HDL-C and decrease in ApoB.64
Despite these favorable effects in LDL particles, off-
Table III. Eligibility Criteria
Inclusion Criteria
• Fasting TG ≥ 200 mg/dL (2.26 mmol/L) and b500 mg/dL (5.65 mmol/L)
• HDL-C ≤40 mg/dL (1.03 mmol/L)
• Type2 diabetes of longer than 12weeks duration documented inmedical records, for example: local laboratory evidence throughmedical record reviewof
elevated HbA1c (≥ 6.5% [48 mmol/mol]), elevated plasma glucose (fasting ≥126 mg/dL [7.0 mmol/L]), 2-hour ≥200 mg/dL [11.1 mmol/L] during oral
glucose tolerance testing, or random value ≥200 mg/dL with classic symptoms, or currently taking medication for treatment of diabetes; AND either
a) Age ≥ 50 years if male or ≥ 55 years if female (primary prevention cohort); OR
b) Age ≥ 18 years and established systemic atherosclerosis (secondary prevention cohort; Table IV)
• Participants must be either:
a) Receiving treatment with a stable dose (ie, for at least 12 weeks) of a qualifying moderate- to high-intensity statin (atorvastatin ≥40 mg/day,
rosuvastatin ≥20 mg/day, simvastatin ≥40 mg/day⁎, or pitavastatin 4 mg/day); or
b) Have evidence of LDL-C ≤70 mg/dL (1.81 mmol/L) by local laboratory determination within the previous 12 months#, or
c) Statin intolerant† and have evidence of LDL-C ≤100 mg/dL (2.59 mmol/L) by local laboratory determination within the previous 12 months
• Ability to understand and comply with study procedures and give written informed consent
Exclusion Criteria
• Current or planned use of fibrates or agents with potent peroxisome proliferator activated receptor (PPAR)-α agonist activity (eg, saroglitazar) within 6
weeks of enrollment.
• Known sensitivity to PPAR-α agonists or tablet excipients
• Initiation of, or change in, current TG-lowering therapy within 12 weeks of enrollment
• Type 1 diabetes mellitus
• Uncontrolled diabetes mellitus as defined by a HbA1c N9.5% [80 mmol/mol]
• Untreated or inadequately treated hypothyroidism [thyroid stimulating hormone (TSH) N2.0 × the upper limit of normal (ULN) or free thyroxine (T4)
≤ the lower limit of normal] or hyperthyroidism; controlled thyroid disease (permitted) requires normal TSH and stable therapy for at least 4 weeks
• Recent CVD event (eg, MI or stroke) within 8 weeks of randomization
• Recent or planned vascular intervention within 8 weeks of randomization
• New York Heart Association Class IV heart failure
• Known homozygous familial hypercholesterolemia (heterozygous is permitted) or familial hypoalphalipoproteinemia
• Documented previous occurrence of myositis/myopathy
• Unexplained creatine kinase (CK) N5× ULN
• Liver disease defined as cirrhosis or Child-Pugh class B and C, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) N3× ULN
• Biliary obstruction or hyperbilirubinemia (ie, total bilirubin N2× ULN, except with a documented diagnosis of Gilbert's disease)
• Chronic renal insufficiency, defined by an estimated glomerular filtration rate (eGFR)
• b30 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration
• (CKD-EPI) formula or kidney transplant, regardless of renal function
• Unexplained anemia (hematocrit ≤30%)
• Uncontrolled hypertension (seated systolic blood pressure N160 mmHg and/or diastolic blood pressure N100 mmHg) at randomization.
• History of chronic active hepatitis B or hepatitis C, or known infection with human immunodeficiency virus (HIV); participants with documented
hepatitis C resolution after treatment are permitted
• Active malignancy, except non-melanoma skin cancer or carcinoma in situ of the cervix, within the last 2 years.
• Prior organ transplant or any condition likely to lead to organ transplantation in the next 5 years
• Current or anticipated chronic use of cyclosporine, rifampicin, or other inhibitors of organic anion transporting polypeptides (OATP)1B1, or OATP1B3
• History of alcoholism or unwillingness to limit alcohol intake to b15 alcoholic beverages (or units) per week or b5 alcoholic beverages (or units) during a
single occasion for men and b8 alcoholic beverages (or units) per week or b4 alcoholic beverages (or units) during a single occasion for women during the
study period. Note: One alcoholic beverage (unit) is defined as 12 oz. (350 mL) of beer, 5 oz. (150 mL) of wine, or 1.5 oz. (45 mL) of liquor
• History of hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• Women who are pregnant, lactating, planning to be pregnant or lactating during the study period, or WOCP who are not using an acceptable method of
contraception
• A medical condition, other than vascular disease, with life expectancy b3 years, which might prevent the participant from completing the study
• Any factors likely to limit adherence to the study medications and procedures, such as substance abuse, dementia, plans to move within the next 2
years, and/or history of noncompliance with medication or scheduled appointments, and
• Participation in another clinical study at the time of informed consent, or has received an investigational drug within 90 days before signing the
informed consent for this study.
⁎ Participants enrolled on simvastatin N40 mg/day must have been taking and tolerating that dose for at least 12 months.
# If untreated or on stable dosing (ie, for at least 12 weeks) of another lipid-lowering regimen that may include a statin with or without ezetimibe and/or a PCSK9 inhibitor
†Statin intolerance is defined as: the inability to tolerate at least 2 statins: 1 statin at the lowest daily starting dose (defined as rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg,
lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg or pitavastatin 2 mg), AND another statin at any dose, due to skeletal muscle-related symptoms, other than those due to strain
or trauma, such as pain, aches, weakness, or cramping, that begins or increases during statin therapy and stops when statin therapy is discontinued. Participants not receiving a daily
regimen of a statin (e.g., 1–3 times weekly) could also be considered “statin intolerant” if they cannot tolerate a cumulative weekly statin dose of 7 times the lowest approved tablet size,
and the criteria outlined above are also met.
88 Pradhan et al
American Heart Journal
December 2018protocol LDL-C measurement and resultant changes to
statin dosing or addition of other LDL-C lowering
therapies may lead to an undesirable imbalance in useof these agents between the two treatment arms. Thus,
central monitoring of ApoB levels and an algorithm to
standardize changes in lipid-lowering therapy is used to
Table IV. PROMINENT secondary prevention cohort eligibility
• Prior MI or ischemic (non-hemorrhagic) stroke
• Coronary angiographic lesion of ≥60% stenosis in a major epicardial vessel or ≥50% left main stenosis
• Asymptomatic carotid disease with ≥70% carotid artery stenosis
• Symptomatic carotid disease with ≥50% carotid artery stenosis
• Symptomatic lower extremity peripheral artery disease (PAD) (ie, intermittent claudication, rest pain, lower extremity ischemic ulceration, or major
amputation with either ankle-brachial index ≤0.9 or other diagnostic testing [eg, toe-brachial index, angiogram, or other imaging study])
• Prior arterial revascularization procedure (including coronary, carotid, or peripheral angioplasty/stenting, bypass, or atherectomy/endarterectomy)
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In brief, while investigators remain blinded to post-
randomization lipid values, they are notified when
elevations in ApoB occur and if persistent, a recommen-
dation is issued for lipid lowering drug titration in the
increments provided (Supplemental Figure 2). The
electronic reporting system captures any resulting
changes to therapy.
Safety evaluations and adverse events
Safety evaluations include an assessment of adherence,
monitoring of clinical chemistry variables related to
safety, side effects, and any reported adverse events.
Adverse events will be categorized as serious or non-
serious and will be graded by investigators with respect
to the possibility of relatedness to the study drug. In
addition, a number of pre-specified adverse events and
events of clinical interest are collected at each study visit
(Supplementary Table II). Occurrence of any of these
events prompts further investigation including collection
of information pertaining to diagnostic testing and/or
therapeutic interventions. Muscle-related adverse events
and the occurrence of liver disease, designated events of
special interest, will be monitored rigorously throughout
the trial.
Sample size
PROMINENT is an event-driven trial that is designed to
continue until at least 1092 participants (with a minimum
of 200 women) experience a confirmed primary efficacy
outcome. The recruitment goal for women is 20% of the
total randomized population. The planned sample size of
approximately 10,000 subjects was chosen on the basis of
the following assumptions: a 2-arm study with 1:1
randomization, interim efficacy and futility monitoring,
overall 2-sided type I error level of 5%, an annual event
rate in the placebo control group of 3.5 to 4.5%, 10% non-
adherence, 1% annual loss to follow-up, and 90% power
to detect an 18% reduction in the relative hazard with
pemafibrate. The current trial design provides 80% power
to detect a 15% reduction in HR and 60% power to detect
a 12% reduction. The expectation for duration of
recruitment is 2.5 years. Loss to follow-up is expected
to be low as participants are assumed to have a strong
affiliation with their treatment centers, will have under-
gone assessment for adherence to study proceduresduring the placebo run-in period, provide next-of-kin
contact information, and a retention protocol is in place
to minimize drop out during the trial. The total expected
treatment period is 5 years with an expected average
follow-up period of 3.75 years.
Analyses
Analysis of the primary outcome will be based on the
intention to treat principle. Thus, participants will be
analyzed according to their randomized treatment group,
regardless of whether they adhere to their assigned
treatment. The primary endpoint of the study is the time
from randomization to the first occurrence of any
component of the clinical composite endpoint of nonfatal
MI, nonfatal ischemic stroke, hospitalization for unstable
angina requiring urgent coronary revascularization, and
CV death. Comparisons will use a likelihood ratio test
based on a proportional hazards model stratified on sex,
prior history of CVD, and statin use at baseline to test the
null hypothesis of no association between assignment to
pemafibrate and the rate of occurrence of the primary
endpoint. Estimates of the probability of the primary
endpoint by time after randomization within treatment
groups will use the method of Kaplan and Meier.79 If
Kaplan–Meier plots of event-free survival by study time,
or related plots of log(−log)(survival), indicate violations
of the proportional hazards assumption, or a formal test
of trend in the scaled Schoenfeld residuals indicates such
a violation, then weighted log-rank tests will be used
according to strategies described by Pecková and
Fleming.80 However, even in the presence of an apparent
violation of the proportional hazards assumption, the
primary analysis described above gives a valid test of the
main study hypothesis and will remain the primary
analytic strategy, with these weighted log-rank tests
serving as sensitivity analyses. The statistical analysis
plan (Appendix A) provides details of the statistical
approach.
Data safety and monitoring board
A fully independent Data and Safety Monitoring Board
(DSMB) is monitoring enrollment and adherence, bio-
markers for safety and efficacy, serious adverse events,
the occurrence of trial endpoints, and participant and site
burden. Two formal interim analyses to assess efficacy
will occur when approximately 50% and 75% of the
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the study, including implications of interim monitoring
on study power, considered that stopping boundaries are
based on the Haybittle-Peto method. Under this ap-
proach, the Z-values for the boundary at the 50% and 75%
information times correspond to 2-sided P values of
0.001. Additionally, the DSMB will consider the direction
of effect for each of the components of the primary
endpoint as well as the sensitivity analysis for loss to
follow-up, ensuring that the point estimate for each is
consistent with the composite result and there is no
concern for safety. The DSMB will also consider the
direction of the effect in women, again ensuring
consistency with the overall result and no concern for
safety. Specifically, for the study to be stopped early for
efficacy, the point estimate of the HR for the pemafibrate
group compared to placebo must be b1 for each
component of the primary endpoint as well as for the
subgroup of women. Further, the HR of 1.36 seen in
ACCORD55 must not be in the 95% CI for the primary
endpoint in the subgroup of women.
As a guideline for considering a recommendation to
terminate the study early because of convincing evidence
of inefficacy (futility), preplanned inefficacy bounds will
also be considered at accrual of approximately 30%, 50%,
and 75% of primary efficacy outcomes. Based upon the
Linear 10% Inefficacy Boundary approach described by
Freidlin, Korn, and Gray,81 the inefficacy boundary will
be crossed if the observed relative hazard of the primary
outcome associated with pemafibrate assignment is
greater than 1.000 at the first interim futility analysis,
greater than 0.996 at the second interim futility analysis,
or greater than 0.988 at the third interim futility analysis
and the 95% CI excludes the expected effect.
No formal boundaries were set for terminating the
study for safety reasons as this determination will be
made by the DSMB in the presence of clear and consistent
evidence of harm that overwhelms the net benefit. The
formal DSMB Charter is available from the investigators.
Trial organization and management
The trial is independently managed by CCVDP, a
Steering Committee (SC) and an Executive Committee
(EC) in collaboration with the Sponsor, Kowa Research
Institute, and the study Contract Research Organization
(CRO, IQVIA). The trial is registered at www.clinical
trials.gov (NCT03071692). Current membership of the
EC, SC, SAB, Operations Committee (OC), Data Coordi-
nating Center, CEC, Scientific Advisory Committee, and
DSMB is provided in Supplementary Appendix B.
Funding
Drug development, phase two studies and the conduct
of the PROMINENT trial are funded by Kowa Company
Ltd., Tokyo, Japan. No additional funding was used to
support the creation of this paper. No additional fundingwas used to support the creation of this paper. The
authors are solely responsible for the drafting and editing
of the paper and its final contents.Conclusion
A growing body of evidence supports a causal role for
hypertriglyceridemia and TRLs in atherogenesis. Increas-
ing rates of diabetes, obesity, and cardiovascular disease
compels investigation of pharmacologic interventions to
address this mounting global issue. However, no study
has yet tested whether TG lowering therapy in statin-
treated patients with mild-to-moderate TG elevation (and
thus at residual hypertriglyceridemic risk) confers a
cardiovascular benefit. Pemafibrate holds considerable
promise as a potent and selective PPAR-α agonist with a
desirable safety profile and favorable pre-clinical and
clinical data which support an improved risk–benefit
ratio beyond fibrates. PROMINENT will provide rigorous
evaluation of the efficacy and safety of this agent in a large
population with diabetes and dyslipidemia treated with
contemporary standard of care concomitant therapies.
The trial could offer a new option for management of
residual cardiovascular risk in these patients.Acknowledgement
The trial is funded by Kowa Company Ltd., Tokyo,
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